Diverse Mechanisms of Allergen Specific Immunotherapy

Cover Page

Cite item

Full Text

Abstract

Allergen immunotherapy (AIT) is widely used to establish a tolerant immune response and it is currently the only disease modifying treatment. There are different routes to administer the allergen, including subcutaneous, sublingual, intralymphatic, epicutaneous, intradermal, and oral and local nasal allergen immunotherapy. Although the optimal administration route depends on the type of allergen, some patients remain unresponsive and so it is important to predict the outcome before and during treatment. Therefore, there is a need to identify candidate prognostic markers for allergen immunotherapy. Herein, we discuss the recent literature on the molecular mechanisms of AIT.

About the authors

Lacin Cevhertas

Bursa Uludag University

Author for correspondence.
Email: akdism@siaf.uzh.ch
Bursa, Turkey

Mübeccel Akdis

University of Zurich

Email: akdism@siaf.uzh.ch
Davos Wolfgang, Switzerland

References

  1. W. van de Veen, and M. Akdis, “The use of biologics for immune modulation in allergic disease”, Journal of Clinical Investigation, vol. 129, no. 4, pp. 1452-1462, 2019.
  2. O. Cromwell, D. Häfner, and A. Nandy, “Recombinant allergens for specific immunotherapy”, Journal of Allergy and Clinical Immunology, vol. 127, no. 4, pp. 865-872, 2011.
  3. Z.-J. Xie, K. Guan, and J. Yin, “Advances in the clinical and mechanism research of pollen induced seasonal allergic asthma”, American journal of clinical and experimental immunology, vol. 8, no. 1, pp. 1-8, 2019.
  4. O. Palomares, M. Akdis, M. Martín-Fontecha, and C.A. Akdis, “Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells”, Immunological Reviews, vol. 278, no. 1, pp. 219-236, 2017.
  5. R.S. Mueller et al., “Allergen immunotherapy in people, dogs, cats and horses - differences, similarities and research needs”, Allergy: European Journal of Allergy and Clinical Immunology, vol. 73, no. 10, pp. 1989-1999, 2018.
  6. A. Głobińska et al., “Mechanisms of allergen-specific immunotherapy: Diverse mechanisms of immune tolerance to allergens”, Annals of Allergy, Asthma and Immunology, vol. 121, no. 3. American College of Allergy, Asthma and Immunology, pp. 306-312, 01-Sep-2018.
  7. D.E.S. Larenas-Linnemann et al., “National clinical practice guidelines for allergen immunotherapy: An international assessment applying AGREE-II”, Allergy: European Journal of Allergy and Clinical Immunology. 2018. Vol. 73. No. 3. P. 664-672.
  8. M.A. Tosca, A. Licari, R. Olcese, G. Marseglia, O. Sacco, and G. Ciprandi, “Immunotherapy and asthma in children”, Frontiers in Pediatrics, vol. 6, 2018.
  9. H. Hoover, B. Leatherman, M. Ryan, K. McMains, and M. Veling, “Evidence-based dosing of maintenance subcutaneous immunotherapy: a contemporary review of state-of-the-art practice”, International Forum of Allergy and Rhinology, vol. 8, no. 7, pp. 806-816, Jul. 2018.
  10. A. Muraro et al., “EAACI guidelines on allergen immunotherapy: Executive statement”, Allergy: European Journal of Allergy and Clinical Immunology, vol. 73, no. 4, pp. 739-743, 2018.
  11. M. Jutel et al., “International consensus on allergy immunotherapy”, Journal of Allergy and Clinical Immunology, vol. 136, no. 3, pp. 556-568, 2015.
  12. O. Pfaar, H. Lou, Y. Zhang, L. Klimek, and L. Zhang, “Recent developments and highlights in allergen immunotherapy”, Allergy: European Journal of Allergy and Clinical Immunology, vol. 73, no. 12, pp. 2274-2289, 2018.
  13. F. Porcaro, G. Corsello, and G.B. Pajno, “SLIT’s Prevention of the Allergic March”, Current Allergy and Asthma Reports, vol. 18, no. 5, 2018.
  14. H. Nolte and J. Maloney, “The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases”, Allergology International, vol. 67, no. 3, pp. 301-308, 2018.
  15. C. Blanco, R. Bazire, L. Argiz, and J. Hernández-Peña, “Sublingual allergen immunotherapy for respiratory allergy: A systematic review”, Drugs in Context, vol. 7, 2018.
  16. K. Lund, H. Kito, M.B. Skydtsgaard, H. Nakazawa, K. Ohashi-Doi, and S. Lawton, “The Importance of Tablet Formulation on Allergen Release Kinetics and Efficiency: Comparison of Freeze-dried and Compressed Grass Pollen Sublingual Allergy Immunotherapy Tablet Formulations”, Clinical Therapeutics, vol. 41, no. 4, pp. 742-753, 2019.
  17. R.L. Wasserman et al., “Reaching for best practices in food oral immunotherapy: Report on the second annual Food Allergy Support Team meeting”, Annals of Allergy, Asthma and Immunology, vol. 123, no. 2, pp. 129-130.e2, 2019.
  18. K. ichi Nagakura et al., “Low-dose oral immunotherapy for children with anaphylactic peanut allergy in Japan”, Pediatric Allergy and Immunology, vol. 29, no. 5, pp. 512-518, 2018.
  19. J. Mäntylä et al., “The effect of oral immunotherapy treatment in severe IgE mediated milk, peanut, and egg allergy in adults”, Immunity Inflammation and Disease, vol. 6, no. 2, pp. 307-311, Jun. 2018.
  20. D.K. Chu et al., “Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety”, The Lancet, vol. 393, no. 10187, pp. 2222-2232, 2019.
  21. U. Nurmatov et al., “Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis”, Allergy: European Journal of Allergy and Clinical Immunology, vol. 72, no. 8, pp. 1133-1147, 2017.
  22. G. Senti et al., “Intralymphatic Immunotherapy: Update and Unmet Needs”, International Archives of Allergy and Immunology, vol. 178, no. 2, pp. 141-149, 2019.
  23. S. Esposito et al., “Epicutaneous immunotherapy in rhino-conjunctivitis and food allergies: A review of the literature”, Journal of Translational Medicine, vol. 16, no. 1, 2018.
  24. J.A. Bird, M. Sánchez-Borges, I.J. Ansotegui, M. Ebisawa, and J.A.O. Martell, “Skin as an immune organ and clinical applications of skin-based immunotherapy”, World Allergy Organization Journal, vol. 11, no. 1, 2018.
  25. G. Senti et al., “Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy”, Journal of Allergy and Clinical Immunology, vol. 124, no. 5, pp. 997-1002, 2009.
  26. L. Mondoulet, V. Dioszeghy, M. Ligouis, V. Dhelft, C. Dupont, and P.H. Benhamou, “Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy”, Clinical and Experimental Allergy, vol. 40, no. 4, pp. 659-667, 2010.
  27. A.W. Burks, H.A. Sampson, M. Plaut, G. Lack, and C.A. Akdis, “Treatment for food allergy”, Journal of Allergy and Clinical Immunology, vol. 141, no. 1. pp. 1-9, 2018.
  28. G. Du et al., “Intradermal vaccination with hollow microneedles: A comparative study of various protein antigen and adjuvant encapsulated nanoparticles”, Journal of Controlled Release, vol. 266, pp. 109-118, 2017.
  29. J.J. Tsai, E.C. Liao, F.H. Tsai, C.C. Hsieh, and M.F. Lee, “The effect of local nasal immunotherapy in allergic rhinitis: Using strips of the allergen dermatophagoides pteronyssinus”, Journal of Asthma, vol. 46, no. 2, pp. 165-170, 2009.
  30. G.B. Pajno et al., “Children’s compliance with allergen immunotherapy according to administration routes [1]”, Journal of Allergy and Clinical Immunology, vol. 116, no. 6, pp. 1380-1381, 2005.
  31. B.N. Lambrecht and H. Hammad, “The immunology of the allergy epidemic and the hygiene hypothesis”, Nature Immunology, vol. 18, no. 10. pp. 1076-1083, 2017.
  32. H.A. Sampson, L. O’Mahony, A.W. Burks, M. Plaut, G. Lack, and C.A. Akdis, “Mechanisms of food allergy”, Journal of Allergy and Clinical Immunology, vol. 141, no. 1, pp. 11-19, Jan. 2018.
  33. C.A. Akdis and M. Akdis, “Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens”, World Allergy Organization Journal, vol. 8, no. 1, 2015.
  34. C. Möbs, C. Slotosch, H. Löffler, T. Jakob, M. Hertl, and W. Pfützner, “Birch Pollen Immunotherapy Leads to Differential Induction of Regulatory T Cells and Delayed Helper T Cell Immune Deviation”, The Journal of Immunology, vol. 184, no. 4, pp. 2194-2203, 2010.
  35. S. Radulovic, M.R. Jacobson, S.R. Durham, and K.T. Nouri-Aria, “Grass pollen immunotherapy induces Foxp3-expressing CD4+CD25+ cells in the nasal mucosa”, Journal of Allergy and Clinical Immunology, vol. 121, no. 6, pp. 1467-1472, 2008.
  36. W. Van De Veen et al., “IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses”, Journal of Allergy and Clinical Immunology, vol. 131, no. 4, pp. 1204-1212, 2013.
  37. T. Boonpiyathad et al., “Role of Der p 1-specific B cells in immune tolerance during 2 years of house dust mite-specific immunotherapy”, Journal of Allergy and Clinical Immunology, vol. 143, no. 3, pp. 1077-1086.e10, 2019.
  38. S.N. Freiberger, M. Zehnder, G. Gafvelin, H. Grönlund, T.M. Kündig, and P. Johansen, “IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT-Feld1 in human”, Allergy: European Journal of Allergy and Clinical Immunology, vol. 71, no. 9, pp. 1366-1370, 2016.
  39. A. Slovick et al., “A randomised placebo-controlled trial investigating efficacy and mechanisms of low-dose intradermal allergen immunotherapy in treatment of seasonal allergic rhinitis”, Efficacy and Mechanism Evaluation, vol. 3, no. 10, pp. 1-80, Dec. 2016.
  40. Y. Liu and J.-J. Tsai, “Production of Salivary Immunoglobulin A and Suppression of Dermatophagoides pteronyssinus-Induced Airway Inflammation by Local Nasal Immunotherapy”, Int Arch Allergy Immunol, vol. 138, no. 2, 2005.
  41. C.T. Cady et al., “IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcγRIIA and FcγRIIB”, Immunology Letters, vol. 130, no. 1-2, pp. 57-65, 2010.
  42. D. MacGlashan and R.G. Hamilton, “Parameters determining the efficacy of CD32 to inhibit activation of FcϵRI in human basophils”, Journal of Allergy and Clinical Immunology, vol. 137, no. 4, pp. 1256-1258.e11, 2016.
  43. C.A. Akdis and M. Akdis, “Mechanisms of immune tolerance to allergens: Role of IL-10 and Tregs”, Journal of Clinical Investigation, vol. 124, no. 11, pp. 4678-4680, Nov. 2014.
  44. M. Akdis et al., “Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells”, Journal of Experimental Medicine, vol. 199, no. 11, pp. 1567-1575, 2004.
  45. T. Boonpiyathad et al., “Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy”, Allergy: European Journal of Allergy and Clinical Immunology, vol. 74, no. 5, pp. 976-985, 2019.
  46. Y.G. Tsai, K.D. Yang, Y.S. Wen, C.H. Hung, J.W. Chien, and C.Y. Lin, “Allergen-specific immunotherapy enhances CD8+ CD25+ CD137+ regulatory T cells and decreases nasal nitric oxide”, Pediatric Allergy and Immunology, 2019.
  47. A. Syed et al., “Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3)”, Journal of Allergy and Clinical Immunology, vol. 133, no. 2, pp. 500-510, 2014.
  48. L. Mondoulet et al., “Gata3 hypermethylation and Foxp3 hypomethylation are associated with sustained protection and bystander effect following epicutaneous immunotherapy in peanut-sensitized mice”, Allergy: European Journal of Allergy and Clinical Immunology, vol. 74, no. 1, pp. 152-164, 2019.
  49. J.F. Ryan et al., “Successful immunotherapy induces previously unidentified allergen-specific CD4+ T-cell subsets”, Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 9, pp. E1286-E1295, 2016.
  50. D. Zemmour, R. Zilionis, E. Kiner, A.M. Klein, D. Mathis, and C. Benoist, “Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR article”, Nature Immunology, vol. 19, no. 3, pp. 291-301, 2018.
  51. E. Wambre et al., “A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders”, Science Translational Medicine, vol. 9, no. 401, 2017.
  52. E. Wambre, “Effect of allergen-specific immunotherapy on CD4+ T cells”, Current Opinion in Allergy and Clinical Immunology, vol. 15, no. 6, pp. 581-587, 2015.
  53. G.W. Scadding et al., “Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: The GRASS randomized clinical trial”, JAMA - Journal of the American Medical Association, vol. 317, no. 6, pp. 615-625, 2017.
  54. F. Ihara et al., “Identification of specifically reduced Th2 cell subsets in allergic rhinitis patients after sublingual immunotherapy”, Allergy: European Journal of Allergy and Clinical Immunology, vol. 73, no. 9, pp. 1823-1832, 2018.
  55. V. Schulten et al., “Allergen-specific immunotherapy modulates the balance of circulating Tfh and Tfr cells”, Journal of Allergy and Clinical Immunology, vol. 141, no. 2, pp. 775-777.e6, 2018.
  56. Y. Yao, Z.C. Wang, D. Yu, and Z. Liu, “Role of allergen-specific T-follicular helper cells in immunotherapy”, Current Opinion in Allergy and Clinical Immunology, vol. 18, no. 6, pp. 495-501, 2018.
  57. W. Van De Veen, “The role of regulatory B cells in allergen immunotherapy”, Current Opinion in Allergy and Clinical Immunology, vol. 17, no. 6, pp. 447-452, 2017.
  58. U.M. Zissler et al., “Early IL-10 producing B-cells and coinciding Th/Tr17 shifts during three year grass-pollen AIT”, EBioMedicine, vol. 36, pp. 475-488, Oct. 2018.
  59. B. Stanic et al., “IL-10-overexpressing B cells regulate innate and adaptive immune responses”, Journal of Allergy and Clinical Immunology, vol. 135, no. 3, pp. 771-780.e8, 2015.
  60. T. Boonpiyathad et al., “High-dose bee venom exposure induces similar tolerogenic B-cell responses in allergic patients and healthy beekeepers”, Allergy: European Journal of Allergy and Clinical Immunology, vol. 72, no. 3, pp. 407-415, 2017.
  61. S.U. Patil et al., “Peanut oral immunotherapy transiently expands circulating Ara h 2-specific B cells with a homologous repertoire in unrelated subjects”, Journal of Allergy and Clinical Immunology, vol. 136, no. 1, pp. 125-134.e12, 2015.
  62. J. Mjösberg and H. Spits, “Human innate lymphoid cells”, Journal of Allergy and Clinical Immunology, vol. 138, no. 5, pp. 1265-1276, Nov. 2016.
  63. T. Hoyler et al., “The Transcription Factor GATA-3 Controls Cell Fate and Maintenance of Type 2 Innate Lymphoid Cells”, Immunity, vol. 37, no. 4, pp. 634-648, 2012.
  64. T.Y.F. Halim, A. MacLaren, M.T. Romanish, M.J. Gold, K.M. McNagny, and F. Takei, “Retinoic-Acid-Receptor-Related Orphan Nuclear Receptor Alpha Is Required for Natural Helper Cell Development and Allergic Inflammation”, Immunity, vol. 37, no. 3, pp. 463-474, 2012.
  65. V. Lombardi et al., “Circulating innate lymphoid cells are differentially regulated in allergic and nonallergic subjects”, Journal of Allergy and Clinical Immunology, vol. 138, no. 1, pp. 305-308, 2016.
  66. W. Mitthamsiri, P. Pradubpongsa, A. Sangasapaviliya, and T. Boonpiyathad, “Decreased CRTH2 expression and response to allergen re-stimulation on innate lymphoid cells in patients with allergen-specific immunotherapy”, Allergy, Asthma and Immunology Research, vol. 10, no. 6, pp. 662-674, 2018.
  67. M. Lao-Araya, E. Steveling, G.W. Scadding, S.R. Durham, and M.H. Shamji, “Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy”, Journal of Allergy and Clinical Immunology, vol. 134, no. 5, pp. 1193-1195.e4, 2014.
  68. J. Eckl-Dorna et al., “Allergen-specific antibodies regulate secondary allergen-specific immune responses”, Frontiers in Immunology, vol. 10, no. JAN, p. 3131, Jan. 2019.
  69. Y. Tanaka, S. Fukumoto, and S. Sugawara, “Mechanisms underlying the induction of regulatory T cells by sublingual immunotherapy”, Journal of Oral Biosciences, vol. 61, no. 2, pp. 73-77, 2019.
  70. T. Worbs et al., “Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells”, Journal of Experimental Medicine, vol. 203, no. 3, pp. 519-527, Mar. 2006.
  71. B. Johansson-Lindbom et al., “Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing”, Journal of Experimental Medicine, vol. 202, no. 8, pp. 1063-1073, Oct. 2005.
  72. C. Bussmann, J. Xia, J.P. Allam, L. Maintz, T. Bieber, and N. Novak, “Early markers for protective mechanisms during rush venom immunotherapy”, Allergy: European Journal of Allergy and Clinical Immunology, vol. 65, no. 12, pp. 1558-1565, 2010.
  73. G. Matteoli et al., “Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction”, Gut, vol. 59, no. 5, pp. 595-604, 2010.
  74. R. Jiménez-Saiz and S.U. Patil, “The Multifaceted B Cell Response in Allergen Immunotherapy”, Current Allergy and Asthma Reports, vol. 18, no. 12, 2018.
  75. T.S. Dodev et al., “Inhibition of allergen-dependent IgE activity by antibodies of the same specificity but different class”, Allergy: European Journal of Allergy and Clinical Immunology, vol. 70, no. 6, pp. 720-724, 2015.
  76. O.T. Burton et al., “Oral immunotherapy induces IgG antibodies that act through FcγRIIb to suppress IgE-mediated hypersensitivity”, Journal of Allergy and Clinical Immunology, vol. 134, no. 6, pp. 1310-1317.e6, 2014.
  77. A. Maeta, R. Katahira, M. Matsushima, H. Onishi, Y. Nakamura, and K. Takahashi, “Stepwise oral immunotherapy for 10 days in an egg-white allergy mouse model did not ameliorate the severity of allergy but induced the production of allergen-specific IgA”, Bioscience, Biotechnology and Biochemistry, vol. 82, no. 12, pp. 2176-2179, 2018.
  78. B.L. Wright et al., “Component-resolved analysis of IgA, IgE, and IgG4 during egg OIT identifies markers associated with sustained unresponsiveness”, Allergy: European Journal of Allergy and Clinical Immunology, vol. 71, no. 11, pp. 1552-1560, 2016.
  79. C.A. Jakwerth et al., “Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: An EAACI position paper”, Allergologie, vol. 41, no. 9, pp. 376-385, 2018.
  80. M. Caruso et al., “Basophil biomarkers as useful predictors for sublingual immunotherapy in allergic rhinitis”, International Immunopharmacology, vol. 60, pp. 50-58, 2018.
  81. M.H. Shamji et al., “Basophil expression of diamine oxidase: A novel biomarker of allergen immunotherapy response”, Journal of Allergy and Clinical Immunology, vol. 135, no. 4, pp. 913-921.e9, 2015.
  82. M.A. Calderõn et al., “Allergen immunotherapy: A new semantic framework from the European Academy of Allergy and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report”, Allergy: European Journal of Allergy and Clinical Immunology, vol. 68, no. 7. pp. 825-828, 2013.
  83. S.B. Sindher, A. Long, S. Acharya, V. Sampath, and K.C. Nadeau, “The Use of Biomarkers to Predict Aero-Allergen and Food Immunotherapy Responses”, Clinical Reviews in Allergy and Immunology, vol. 55, no. 2. pp. 190-204, 2018.
  84. S.D. Narisety et al., “A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy”, Journal of Allergy and Clinical Immunology, vol. 135, no. 5, pp. 1275-1282.e6, 2015.
  85. G. Di Lorenzo et al., “Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy”, Journal of Allergy and Clinical Immunology, vol. 123, no. 5, pp. 1103-1110, 2009.
  86. G.B. Karakoc, M. Yilmaz, D.U. Altıntaş, and S.G. Kendirli, “Can Serum-Specific IgE/Total IgE Ratio Predict Clinical Response to Allergen-Specific Immunotherapy in Children Monosensitized to House Dust Mite?”, Journal of Allergy, vol. 2012, pp. 1-5, 2012.
  87. J. Chen et al., “Specific immunoglobulin e and immunoglobulin G4 toward major allergens of house-dust mite during allergen-specific immunotherapy”, American Journal of Rhinology and Allergy, vol. 31, no. 3, pp. 156-160, 2017.
  88. M. Feng et al., “Functional and Immunoreactive Levels of IgG4 Correlate with Clinical Responses during the Maintenance Phase of House Dust Mite Immunotherapy”, The Journal of Immunology, vol. 200, no. 12, pp. 3897-3904, Jun. 2018.
  89. A. Santosa et al., “Evaluation of the applicability of the Immuno-solidphase allergen chip (ISAC) assay in atopic patients in Singapore”, Clinical and Translational Allergy, vol. 5, no. 1, 2015.
  90. J.M. Orengo et al., “Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement”, Nature Communications, vol. 9, no. 1, 2018.
  91. O. Palomares, L. O’Mahony, and C.A. Akdis, “The many routes of dendritic cells to ensure immune regulation”, Journal of Allergy and Clinical Immunology, vol. 127, no. 6, pp. 1541-1542, 2011.
  92. A. Suárez-Fueyo et al., “Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation”, Journal of Allergy and Clinical Immunology, vol. 133, no. 1, 2014.
  93. P.L. Smaldini, F. Trejo, J.L. Cohen, E. Piaggio, and G.H. Docena, “Systemic IL-2/anti-IL-2Ab complex combined with sublingual immunotherapy suppresses experimental food allergy in mice through induction of mucosal regulatory T cells”, Allergy: European Journal of Allergy and Clinical Immunology, vol. 73, no. 4, pp. 885-895, 2018.
  94. M.H. Shamji and S.R. Durham, “Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers”, Journal of Allergy and Clinical Immunology, vol. 140, no. 6, pp. 1485-1498, Dec. 2017.
  95. C. Gueguen et al., “Changes in markers associated with dendritic cells driving the differentiation of either T H 2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy”, Journal of Allergy and Clinical Immunology, vol. 137, no. 2, pp. 545-558, 2016.
  96. A. Zimmer et al., “A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy”, Journal of Allergy and Clinical Immunology, vol. 129, no. 4, pp. 1020-1030, 2012.
  97. S.R. Durham et al., “SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial”, Journal of Allergy and Clinical Immunology, vol. 129, no. 3, 2012.
  98. G. Du Toit et al., “Randomized trial of peanut consumption in infants at risk for peanut allergy”, New England Journal of Medicine, vol. 372, no. 9, pp. 803-813, 2015.
  99. R. Valenta, R. Campana, M. Focke-Tejkl, and V. Niederberger, “Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future”, Journal of Allergy and Clinical Immunology, vol. 137, no. 2, pp. 351-357, 2016.
  100. A. Renand et al., “Synchronous immune alterations mirror clinical response during allergen immunotherapy”, Journal of Allergy and Clinical Immunology, vol. 141, no. 5, pp. 1750-1760.e1, May 2018.

Copyright (c) 2019 Cevhertas L., Akdis M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies